Mycophenolate mofetil in primary central nervous system vasculitis

Carlo Salvarani, Robert D. Brown, Teresa J H Christianson, John Huston, Caterina Giannini, Dylan V. Miller, Francesco Muratore, Gene G. Hunder

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To evaluate the efficacy and safety of mycophenolate mofetil (MMF) in adult primary central nervous system vasculitis (PCNSV). Methods: We studied a cohort of 163 patients with PCNSV who were seen at the Mayo Clinic from 1983 to 2011. We compared patients treated with MMF and those receiving other therapies. Results: We identified 16 patients treated with MMF. MMF in combination with GCs achieved a favorable response in most patients. A significant proportion of patients treated with MMF had a less severe disability at last follow-up compared to those receiving other therapies (p = 0.023) and cyclophosphamide and prednisone (p = 0.017). No statistically significant differences were observed regarding relapses and ability to discontinue therapy at last follow-up. A trend to a more favorable treatment response was observed in patients treated with MMF compared to those treated with other therapies (p = 0.075). Only 1 patient suspended MMF for severe leukopenia. Conclusion: MMF seems to be an effective and safe therapy for adult PCNSV.

Original languageEnglish
Pages (from-to)55-59
Number of pages5
JournalSeminars in Arthritis and Rheumatism
Volume45
Issue number1
DOIs
Publication statusPublished - Aug 1 2015

Keywords

  • Mycophenolate mofetil
  • PCNSV
  • Therapy
  • Vasculitis

ASJC Scopus subject areas

  • Rheumatology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Mycophenolate mofetil in primary central nervous system vasculitis'. Together they form a unique fingerprint.

Cite this